Insight

Photo from Aren Karapetyan/LinkedIn

Sep 24, 2024, 08:51

Aren Karapetyan: New Insights on Treatment for Squamous Cell Carcinoma of the Anus

Aren Karapetyan, Oncology Resident at Yerevan State Medical University, shared a post on LinkedIn:

“New Insights on Treatment for Squamous Cell Carcinoma of the Anus (SCCA).

A recent study explores the use of weekly cisplatin as a chemoradiotherapy (CRT) option for SCCA, offering promising results with reduced toxicity compared to traditional regimens.

Key findings:

Safe and effective: Weekly cisplatin showed an acceptable acute toxicity profile and good outcomes.
Improved compliance: Lower hematological toxicity was observed compared to historical data.
Positive outcomes: 5-year Disease-Free Survival (DFS) was 77%, with Overall Survival (OS) at 86%.
This approach may offer a more tolerable option for patients while maintaining high treatment efficacy.”

“Feasibility of weekly cisplatin and radiotherapy for localized anal cancer – A Danish anal cancer group report”

Authors: Anne Vittrup Jakobsen, Camilla Jensenius Skovhus Kronborg, Rikke Kjer Oksen, Birgitte Mayland Havelund, Karen Lycke Wind, Karen-Lise Garm Spindler

Aren Karapetyan: New Insights on Treatment for Squamous Cell Carcinoma of the Anus

Source: Aren Karapetyan/LinkedIn

More posts featuring Aren Karapetyan on oncodaily.com

Anne Vittrup Jakobsen Aren Karapetyan Birgitte Mayland Havelund Camilla Jensenius Skovhus Kronborg cancer chemoradiotherapy Cisplatin CRT Karen Lycke Wind Karen-Lise Garm Spindler OncoDaily Oncology Radiotherapy and Oncology Rikke Kjer Oksen SCCA

FDA approval: Pembrolizumab for HER2 positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥1): KEYNOTE-811 Trial

Changing the Future of Adolescent and Young Adult Cancer Care

OncoDaily Launches New Social Channel on Telegram – @OncoDaily

In Memory of Chadwick Boseman and His Colon Cancer Battle

Groundbreaking Canadian Cancer Society-funded research aims to reshape the future of advanced cancer